Brand Logo of Anderson Diagnostics
An illustrative depiction of the Genetic Testing in Lung Cancer.
Genetic Testing in Lung Cancer
Identification of actionable mutations, deletions and driver gene fusions in NSCLC and SCLC can help guide targeted treatment regimens
Testing Solutions
Target Genes

3. MET
4. ERBB2
6. ALK
7. RET
8. ROS
9. NTRK + PDL-1

Highlights of Genetic Testing Panel

  • Liquid Biopsy - Cell free DNA for EGFR available
  • TAT for complete Oncomine Panel 2 weeks only
  • Tests available individually also
  • Fresh tissue / FFPE block accepted
Includes Mutations, Deletions, Fusion genes and PDL-1 overexpression commonly reported in NSCLC and SCLC
EFGR - by Liquid Biopsy

Individual Testing Solutions for Lung Cancer

EGFR Mutation Testing*
To detect mutations in the EGFR gene for the detection of 42 mutations 
(exons 18, 19, 20, and 21)
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days
Liquid Biopsy Available
KRAS Mutation Testing
To detect mutations in the KRAS oncogene for detection of 7 mutations in codon 12 and 13
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 5 days
BRAF Mutation Testing
To detect hotspot mutation in V600E codon of exon 15 in the BRAF gene
Sample type – FFPE tissue block
Method – Real time – PCR
TAT – 7 days
To detect the ROS1 gene rearrangement
Sample type – FFPE tissue block
Method – Fluorescence In Situ Hybridization
TAT – 7 days
To detect for ALK gene rearrangement
Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days
PDL - 1 Testing
To detect over expression of PDL-1 by tumor and Immune cells SP-142 Clone Ventana
Sample type – FFPE tissue block
Method – Immunohistochemistry (IHC)
TAT – 4 days
Central Processing Center
Anderson Diagnostics and Labs,
No.26, Rajarathinam Street,
Kilpauk, Chennai - 600010.

Oncomine Focus Assay Panel for Lung Cancer with PDL-1 Testing

  • Hot spot screening of relevant, druggable mutations, copy number changes and fusions for various Cancers

  • ACMG/AMP guidelines-based reporting with drugs and target information

  • NGS based assay eliminates need of multiple technology FISH, IHC, Realtime

  • Complete screening of relevant gene in single sample

Sample Type
FFPE Block or Fresh Tissue in ONCO-Bank
TAT - 2 to 3 weeks
Gene Molecular aberration Prevalence in NSCLC Prevalence in SCC
EGFR Mutations (exons 18 – 21) 28% 9%
BRAF Mutations 5% 4%
MET Mutations 10% 4%
RET Fusions or rearrangements 4% 4%
ERBB2 To detect mutations 7% 5%
KRAS To detect mutations 23% 5%
ALK Fusions or rearrangements 7% 5%
ROS Fusions or rearrangements 4% 8%
NTRK Fusions or rearrangements 3% 6%

(Adapted from

List of FDA Approved Targeted Drugs Covered

Biomarker Drugs Disease
BRAF V600E; BRAF V600K Vemurafenib, Cobimetinib, Dabrafenib, Trametinib, Atezolizumab, Encorafenib Melanoma, NSCLC, CRC
ALK Fusion, EML4-ALK Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib NSCLC
EGFR Cetuximab, Mobocertinib, Afatinib, Gefitinib, Amivantamb, Osimertinib, Erlotinib Lung cancer
ERBB2 Fam-trastuzumab Deruxtecan-nxki NSCLC
KRAS Cetuximab, Panitumumab, Sotorasib CRC, NSCLC
MET, exon skipping Capmatinib NSCLC
RET-Fusions Pralsetinib, Selpercatinib NSCLC
Ros1-fusions Entrectinib, Crizotinib NSCLC
Greams Road
044 43539444
044 43539444
Central Pathology Lab
044 43539444
Central Genetic Lab
044 43539444
Become a PartnerFind My Tests
© 2024 Anderson Diagnostics & Labs. All rights are reserved.
HTML SitemapPrivacy PolicyCareers
Designed by
Digital SEO